Overview

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy With IL-2 Followed by Sequential Immunotherapy With CAPOX Combined With PD-1 Antibody and IL-2 for Locally Advanced Rectal Cancer

Status:
RECRUITING

Trial end date:
2028-10-31

Target enrollment:

Participant gender:

Summary

A Single-Center, Single-Arm Study of Neoadjuvant Short-Course Radiotherapy with IL-2 Followed by Sequential Immunotherapy with CAPOX Combined with PD-1 antibody and IL-2 for Locally Advanced Rectal Cancer

Phase:

PHASE2

Details

Lead Sponsor:

The First Affiliated Hospital with Nanjing Medical University

Treatments:

sintilimab